[113] Kim DS, Kim BW, Hatano E, et al. Surgical
Outcomes of Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A
Korea-Japan Multicenter Study[J]. Ann Surg, 2020, 271(5): 913-21. [114] Zhu XD, Huang C, Shen YH, et al. Downstaging and
Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine
Kinase Inhibitor and Anti-PD-1 Antibody Combinations[J]. Liver Cancer, 2021,
10(4): 320-9. [115] 孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识（2021 版）[J]. 中国实用外科杂志, 2021, 41(06): 618-32. [116] 张雯雯, 胡丙洋, 韩骏, 等. PD-1 抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 26(12): 947-8. [117] He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic
Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib
Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized
Clinical Trial[J]. JAMA Oncol, 2019, 5(7): 953-60. [118] Chen X, Zhang Y, Zhang N, et al. Lenvatinib
combined nivolumab injection followed by extended right hepatectomy is a
feasible treatment for patients with massive hepatocellular carcinoma: a case
report[J]. Onco Targets Ther, 2019, 12:7355-9. [119] He MK, Le Y, Li QJ, et al. Hepatic artery
infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for
massive unresectable hepatocellular carcinoma: a prospective non-randomized
study[J]. Chin J Cancer, 2017, 36(1): 83. [120] Zhang Y, Huang G, Wang Y, et al. Is Salvage
Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma
Patients Downstaged by Transarterial Chemoembolization? Ten Years of
Experience[J]. Oncologist, 2016, 21(12): 1442-9. [121] Lyu N, Kong Y, Mu L, et al. Hepatic arterial
infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced
hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-9. [122] Byun HK, Kim HJ, Im YR, et al. Dose escalation
by intensity modulated radiotherapy in liver-directed concurrent
chemoradiotherapy for locally advanced BCLC stage C hepatocellular
carcinoma[J]. Radiother Oncol, 2019, 133: 1-8. [123] Li B, Qiu J, Zheng Y, et al. Conversion to
Resectability Using Transarterial Chemoembolization Combined With Hepatic
Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular
Carcinoma[J]. Annals of Surgery Open, 2021, 2(2): e057. [124] He MK, Liang RB, Zhao Y, et al. Lenvatinib,
toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib
alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13:
17588359211002720. [125] Wakabayashi H, Okada S, Maeba T, et al. Effect
of preoperative portal vein embolization on major hepatectomy for
advanced-stage hepatocellular carcinomas in injured livers: a reliminary
report[J]. Surg Today, 1997, 27(5): 403-10. [126] 郑树国, 李建伟, 肖乐, 等. 全腹腔镜联合肝脏离断和门静脉结扎的二步肝切除术治疗肝硬化肝癌[J]. 中华消化外科杂志, 2014, 13(7): 502-7. [127] Hong DF, Zhang YB, Peng SY, et al. Percutaneous
Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver
Regeneration: A Minimally Invasive First Step of ALPPS for Hepatocellular
Carcinoma[J]. Ann Surg, 2016, 264(1): e1-2. [128] D'haese JG, Neumann J, Weniger M, et al. Should
ALPPS be Used for Liver Resection in Intermediate-Stage HCC?[J]. Ann Surg
Oncol, 2016, 23(4): 1335-43. [129] Li PP, Huang G, Jia NY, et al. Associating liver
partition and portal vein ligation for staged hepatectomy versus sequential
transarterial chemoembolization and portal vein embolization in staged
hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative
study[J]. Hepatobiliary Surgery and Nutrition, 2020. [130] Wang Z, Peng Y, Hu J, et al. Associating Liver
Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable
Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45
Patients[J]. Ann Surg, 2020, 271(3): 534-41. [131] Shi HY, Wang SN, Wang SC, et al. Preoperative
transarterial chemoembolization and resection for hepatocellular carcinoma: a
nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg
Oncol, 2014, 109(5):487-93. [132] Zhou WP, Lai EC, Li AJ, et al. A prospective,
randomized, controlled trial of preoperative transarterial chemoembolization
for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249(2):
195-202. [133] Kaseb AO, Cao HST, Mohamed YI, et al. Final
results of a randomized, open label, perioperative phase II study evaluating
nivolumab alone or nivolumab plus ipilimumab in patients with resectable
HCC[J]. Journal of Clinical Oncology, 2020, 38(15_suppl): 4599-. [134] Wang Z, Ren Z, Chen Y, et al. Adjuvant
Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After
Resection: A Randomized Controlled Study[J]. Clin Cancer Res, 2018, 24(9):
2074-81. [135] Wei W,
Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after
curative resection for hepatocellular carcinoma patients with solitary tumor
and microvascular invasion: a randomized clinical trial of efficacy and
safety[J]. Cancer Commun (Lond), 2018, 38(1): 61. [136] Chen Q, Shu C, Laurence AD, et al. Effect of
Huaier granule on recurrence after curative resection of HCC: a multicentre,
randomised clinical trial[J]. Gut, 2018, 67(11): 2006-16. [137] Huang G, Li PP, Lau WY, et al. Antiviral Therapy
Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA
Levels: A Randomized Controlled Trial[J]. Ann Surg, 2018, 268(6): 943-54. [138] Yin J, Li N, Han Y, et al. Effect of antiviral
treatment with nucleotide/nucleoside analogs on postoperative prognosis of
hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal
clinical study[J]. J Clin Oncol, 2013, 31(29):3647-55. [139] Huang G, Lau WY, Wang ZG, et al. Antiviral
therapy improves postoperative survival in patients with hepatocellular
carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66. [140] Singal AG, Lim JK, Kanwal F. AGA Clinical
Practice Update on Interaction Between Oral Direct-Acting Antivirals for
Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review[J].
Gastroenterology, 2019, 156(8):2149-57. [141] Fan J, Zhou J, Wu ZQ, et al. Efficacy of
different treatment strategies for hepatocellular carcinoma with portal vein
tumor thrombosis[J]. World J Gastroenterol, 2005, 11(8): 1215-9. [142] Lo CM, Liu CL, Chan SC, et al. A randomized,
controlled trial of postoperative adjuvant interferon therapy after resection
of hepatocellular carcinoma[J]. Ann Surg, 2007, 245(6): 831-42. [143] Sun HC, Tang ZY, Wang L, et al. Postoperative
interferon alpha treatment postponed recurrence and improved overall survival
in patients after curative resection of HBV-related hepatocellular carcinoma: a
randomized clinical trial[J]. JCancer Res Clin Oncol, 2006, 132(7): 458-65. [144] Nishiguchi S, Tamori A, Kubo S. Effect of
long-term postoperative interferon therapy on intrahepatic recurrence and
survival rate after resection of hepatitis C virus-related hepatocellular
carcinoma[J]. Intervirology, 2005, 48(1): 71-5. [145] Mazzaferro V, Romito R, Schiavo M, et al.
Prevention of hepatocellular carcinoma recurrence with alpha-interferon after
liver resection in HCV cirrhosis[J]. Hepatology, 2006, 44(6): 1543-54. [146] Ji J, Shi J, Budhu A, et al. MicroRNA
expression, survival, and response to interferon in liver cancer[J]. N Engl J
Med, 2009, 361(15): 1437-47. [147] Sun HC, Zhu XD, Zhou J, et al. Effect of
postoperative apatinib treatment after resection of hepatocellular carcinoma
with portal vein invasion: A phase II study[J]. J Clin Oncol, 2020,
38(4_suppl): abstr 514. [148] Sapisochin G, Bruix J. Liver transplantation for
hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev
Gastroenterol Hepatol, 2017, 14(4): 203-17. [149] Fan J, Yang GS, Fu ZR, et al. Liver transplantation
outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience
in Shanghai, China[J]. J Cancer Res Clin Oncol, 2009, 135(10): 1403-12. [150] Zheng SS, Xu X, Wu J, et al. Liver
transplantation for hepatocellular carcinoma: Hangzhou experiences[J].
Transplantation, 2008, 85(12): 1726-32.
|
